Research and Markets (http://www.researchandmarkets.com/research/3jm4tg/acute_painglobal) has announced the addition of the "Acute Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016" report to their offering.

The Report, Acute Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe.

Key Topics Covered:

  • A snapshot of the global Market and Phase III therapeutics scenario for Acute Pain.
  • A review of the marketed products under prescription for Acute Pain, regulatory information and marketing status.
  • Coverage of global patent coverage and detailed commentaries on the US patent challenges.
  • Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
  • Product profiles for marketed products for Acute Pain with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
  • Coverage of API Manufacturers for Acute Pain drugs in the United States, Europe and Asian Regions with location details.

Benefits of this Report:

  • Evaluate the marketing status and exclusivity details of Acute Pain key products to exploit opportunities for generic drug development opportunities.
  • Identify and understand important and diverse types of therapeutics under Phase III development for Acute Pain.
  • Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Acute Pain.
  • API intelligence over marketed drugs for Acute Pain and gaining primary intelligence over active ingredients manufacturers across the globe.
  • API intelligence over leading Phase III Pipeline drugs.

Report Structure:

1. Indication Overview

2. Market Drugs Landscape

3. Global API Manufacturers Assessment

4. Phase III Drugs Landscape

5. Drugs Market Data and Forecasted Sales Figure-2018

6. Marketed Drugs for Acute Pain

7. Phase III Drugs for Acute Pain

8. Discontinued Drugs for Acute Pain

9. Appendix

10. Methodology

11. Consulting Services

12. Contact Us

13. Disclaimer

For more information visit http://www.researchandmarkets.com/research/3jm4tg/acute_painglobal